|
|
Canada Communicable Disease Report
Volume 27 ACS-5
15 October 2001
An Advisory Committee Statement (ACS)
National Advisory Committee on Immunization (NACI)*
UPDATE ON HEPATITIS A VACCINE
(AVAXIM®, AVENTIS PASTEUR)
Adobe Downloadable Document
(718 KB)
Preamble
The National Advisory Committee on Immunization (NACI) provides
Health Canada with ongoing and timely medical, scientific, and public-health
advice relating to immunization. Health Canada acknowledges that the advice and
recommendations set out in this statement are based upon the best current available
scientific knowledge, and is disseminating this document for information purposes.
Persons administering or using the vaccine should also be aware of the contents
of the relevant product monograph(s). Recommendations for use and other information
set out herein may differ from that set out in the product monograph(s) of the
Canadian licensed manufacturer(s) of the vaccine(s). Manufacturer(s) have only
sought approval of the vaccine(s) and provided evidence as to its safety and
efficacy when used in accordance with the product monographs.
The manufacturer of one of the hepatitis A vaccines licensed
in Canada, (Avaxim®, Aventis Pasteur) has provided revised information
on the content of this vaccine. Each dose (0.5 mL) of Avaxim®
contains:
- HAV antigen units (as defined by the manufacturer) 160
- Aluminum hydroxide
0.3 mg
- 2-phenoxyethanol 2.5
µg
- formaldehyde 12.5
µg
- medium 199, water for injection up to
0.5 mL
- neomycin
trace amounts
This update is a revision of the Supplementary Statement on Hepatitis
A Vaccine (ACS-4), published on 1 July, 2000.
* Members: Dr. V. Marchessault (Chairperson), Dr. J. Spika (Executive
Secretary), J. Brousseau (Administrative Secretary), Dr. I. Bowmer, Dr. G.
De Serres, Dr. S. Dobson, Dr. J. Embree, Dr. I. Gemmill, Dr. J. Langley, Dr.
M. Naus, Dr. P. Orr, Dr. B. Ward, A. Zierler.
Liaison Representatives: S. Callery (CHICA), Dr. J. Carsley (CPHA),
Dr. V. Lentini (DND),Dr. M. Douville-Fradet (ACE), Dr. T. Freeman (CFPC),
Dr. R. Massé (CCMOH), Dr. J. Salzman (CATMAT), Dr. L. Samson, (CIDS),
Dr. D. Scheifele (CAIRE), Dr. M. Wharton (CDC).
Ex-Officio Representatives: Dr. A. King (CIDPC), Dr. L. Palkonyay
(BBR), Dr. P. Riben (MSB).
This statement was prepared by Dr. Ian Gemmilll and approved by NACI.
[Canada Communicable
Disease Report]
|